Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVAXNASDAQ:HCWBNASDAQ:KPRXNASDAQ:ORGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVAXEvaxion Biotech A/S$3.13+21.3%$1.73$1.20▼$18.90$4.39M0.1612,702 shs416,576 shsHCWBHCW Biologics$6.04+1.5%$8.00$5.00▼$100.80$8.69M0.83262,976 shs26,370 shsKPRXKiora Pharmaceuticals$3.08-0.3%$3.03$2.51▼$5.55$9.38M-0.68133,806 shs228,995 shsORGSOrgenesis$1.85+5.7%$2.14$0.87▼$10.80$8.88M0.549,016 shs6,343 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVAXEvaxion Biotech A/S0.00%+28.81%+110.07%+71.04%-81.53%HCWBHCW Biologics0.00%-23.54%+5.59%-57.96%-85.49%KPRXKiora Pharmaceuticals0.00%+1.32%-5.23%-3.45%-27.19%ORGSOrgenesis0.00%-4.64%-11.06%-39.56%+184,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVAXEvaxion Biotech A/S2.7853 of 5 stars3.55.00.00.02.41.70.0HCWBHCW Biologics2.4777 of 5 stars3.52.00.00.02.63.30.0KPRXKiora Pharmaceuticals3.3136 of 5 stars3.85.00.00.02.31.70.6ORGSOrgenesis1.9087 of 5 stars0.05.00.04.40.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVAXEvaxion Biotech A/S 3.00Buy$10.00219.49% UpsideHCWBHCW Biologics 3.00Buy$35.00479.47% UpsideKPRXKiora Pharmaceuticals 3.50Strong Buy$10.00224.68% UpsideORGSOrgenesis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EVAX, ORGS, HCWB, and KPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025HCWBHCW BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $35.004/2/2025EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/28/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVAXEvaxion Biotech A/S$3.29M1.33N/AN/A($5.83) per share-0.54HCWBHCW Biologics$1.45M6.01N/AN/A$0.37 per share16.32KPRXKiora Pharmaceuticals$16M0.59N/AN/A$7.14 per share0.43ORGSOrgenesis$662K13.41N/AN/A($6.58) per share-0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVAXEvaxion Biotech A/S-$22.12M-$1.16N/AN/AN/A-347.83%N/A-79.40%8/12/2025 (Estimated)HCWBHCW Biologics-$24.99M-$23.25N/A∞N/A-1,067.82%-2,516.84%-132.95%N/AKPRXKiora Pharmaceuticals-$12.51M-$2.90N/AN/AN/AN/A21.32%16.39%8/8/2025 (Estimated)ORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)Latest EVAX, ORGS, HCWB, and KPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025EVAXEvaxion Biotech A/S-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A5/15/2025Q1 2025HCWBHCW BiologicsN/A-$0.05N/A-$0.05N/AN/A5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A4/1/2025Q4 2024EVAXEvaxion Biotech A/S-$0.26-$0.07+$0.19-$0.07$1.66 million$0.12 million3/28/2025Q4 2024HCWBHCW BiologicsN/A-$3.20N/A-$0.08N/A$0.40 million3/25/2025Q4 2024KPRXKiora Pharmaceuticals-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVAXEvaxion Biotech A/S7.991.002.80HCWBHCW BiologicsN/A0.070.07KPRXKiora PharmaceuticalsN/A8.978.97ORGSOrgenesisN/A0.070.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVAXEvaxion Biotech A/S11.04%HCWBHCW Biologics2.96%KPRXKiora Pharmaceuticals76.97%ORGSOrgenesis22.56%Insider OwnershipCompanyInsider OwnershipEVAXEvaxion Biotech A/S41.64%HCWBHCW Biologics42.70%KPRXKiora Pharmaceuticals0.05%ORGSOrgenesis5.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVAXEvaxion Biotech A/S601.40 million685,000No DataHCWBHCW Biologics401.44 million22.32 millionNot OptionableKPRXKiora Pharmaceuticals103.04 million2.97 millionNot OptionableORGSOrgenesis1504.80 million4.53 millionNo DataEVAX, ORGS, HCWB, and KPRX HeadlinesRecent News About These CompaniesOrgenesis Delays Filing of Quarterly ReportMay 16, 2025 | tipranks.comOrgenesis Delays 10-K Filing Amid Financial ChallengesApril 1, 2025 | tipranks.comOrgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury TherapiesMarch 6, 2025 | accessnewswire.comOrgenesis Inc. (ORGS) Stock Price, News, Quote & History - Yahoo FinanceFebruary 9, 2025 | finance.yahoo.comOrgenesis secures $5M equity investment from Williamsburg VentureJanuary 29, 2025 | markets.businessinsider.comOrgenesis Inc: Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture HoldingsJanuary 28, 2025 | finanznachrichten.deOrgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture HoldingsJanuary 28, 2025 | accessnewswire.comOrgenesis Inc. Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comOrgenesis Provides Third Quarter 2024 Business UpdateNovember 13, 2024 | markets.businessinsider.comOrgenesis Expands Board with Three New AppointmentsNovember 3, 2024 | markets.businessinsider.comOrgenesis commences trading on OTCQX Best MarketOctober 22, 2024 | markets.businessinsider.comOrgenesis Commences Trading on OTCQX® Best MarketOctober 21, 2024 | markets.businessinsider.comOrgenesis (NASDAQ:ORGS) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.com45O.SG,0P0001J8IU,0 (45O.SG)September 24, 2024 | au.finance.yahoo.comWhy Orgenesis (ORGS) Stock Is Down 23% TodaySeptember 24, 2024 | msn.comOrgenesis Inc.: Orgenesis Announces Reverse Stock SplitSeptember 23, 2024 | finanznachrichten.deOrgenesis Approves 1-for-10 Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comOrgenesis Announces Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comIs Orgenesis Stock (ORGS) a Good Investment?September 19, 2024 | aaii.comOrgenesis Advancing CD19 CAR T-cell Therapy Into Phase I/II Leukemia TrialAugust 31, 2024 | precisionmedicineonline.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVAX, ORGS, HCWB, and KPRX Company DescriptionsEvaxion Biotech A/S NASDAQ:EVAX$3.13 +0.55 (+21.32%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$3.07 -0.06 (-1.79%) As of 06:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.HCW Biologics NASDAQ:HCWB$6.04 +0.09 (+1.51%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$5.73 -0.31 (-5.13%) As of 06/6/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Kiora Pharmaceuticals NASDAQ:KPRX$3.08 -0.01 (-0.32%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$3.02 -0.06 (-1.95%) As of 06:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Orgenesis NASDAQ:ORGS$1.85 +0.10 (+5.71%) As of 06/6/2025 03:59 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
